Top Page
Polynovo
(OTC:PNV)
Polynovo (PNV) vs. iShares MSCI Australia ETF (EWA)
Polynovo Business Overview & Revenue Model
Polynovo Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 127.26M | 127.24M | 103.19M | 65.24M | 41.44M | 29.16M |
| Gross Profit | 76.45M | 122.05M | 97.71M | 19.33M | 16.23M | 7.83M |
| EBITDA | 10.75M | 10.45M | 4.59M | -2.71M | 658.24K | -3.41M |
| Net Income | 13.21M | 13.21M | 5.26M | -4.92M | -1.19M | -4.61M |
Balance Sheet | ||||||
| Total Assets | 127.41M | 127.41M | 108.72M | 92.62M | 34.97M | 38.34M |
| Cash, Cash Equivalents and Short-Term Investments | 33.59M | 33.59M | 45.96M | 46.90M | 6.15M | 7.74M |
| Total Debt | 17.14M | 17.14M | 15.38M | 16.04M | 10.99M | 10.00M |
| Total Liabilities | 44.15M | 44.15M | 36.60M | 27.24M | 17.26M | 15.99M |
| Stockholders Equity | 83.26M | 83.26M | 72.12M | 65.38M | 17.72M | 22.35M |
Cash Flow | ||||||
| Free Cash Flow | -10.68M | -10.78M | 786.00K | -7.46M | -2.55M | -3.82M |
| Operating Cash Flow | 3.25M | 3.15M | 3.68M | -5.93M | -2.06M | -248.74K |
| Investing Cash Flow | -13.93M | -13.22M | -1.49M | -1.53M | 5.86M | -3.57M |
| Financing Cash Flow | -2.39M | -2.39M | -3.17M | 48.06M | -5.39M | -70.37K |
Polynovo Technical Analysis
Polynovo Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$174.55M | -50.00 | -7.26% | ― | 21.65% | 81.40% | |
54 Neutral | AU$849.74M | 64.40 | 16.49% | ― | 23.31% | 151.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$1.84B | -49.51 | -44.49% | ― | 55.91% | 22.60% | |
50 Neutral | AU$105.58M | -7.86 | -31.98% | ― | 34.20% | -23.90% | |
49 Neutral | AU$241.52M | -145.83 | -2.01% | ― | 16.93% | 76.47% | |
44 Neutral | AU$165.43M | -15.52 | -70.55% | ― | ― | -257.32% |
Polynovo Corporate Events
PolyNovo Limited presented at the Bell Potter Healthcare Conference, highlighting its position in the healthcare industry. The company is known for its innovative medical solutions, particularly in the field of advanced wound care. The presentation was intended for general information purposes and emphasized that the information provided is subject to change. PolyNovo disclaimed any liability for the accuracy or completeness of the information, and the presentation did not constitute an offer or recommendation for investment.
At the Annual General Meeting held on October 28, 2025, PolyNovo Limited successfully passed several key resolutions, including the re-election of directors Leon Hoare and David Williams, and the election of Robert Douglas as a director. The adoption of the remuneration report and approval of non-executive directors’ fees were also carried. These outcomes reflect strong shareholder support and are expected to positively impact the company’s governance and strategic direction.
PolyNovo has reported a strong financial year with significant growth in commercial sales and regulatory clearances, expanding its market reach to 46 countries. The company is poised for further growth with the upcoming commercialization of new products and anticipated pricing reforms, supported by a robust cash position and strategic leadership changes.
PolyNovo Limited has announced the resignation of its Chairman, David Williams, with Leon Hoare stepping in as the new Chair. This leadership change aligns with the company’s board succession plans and governance review, ensuring a smooth transition without disrupting operations or strategic direction. Under Williams’ leadership, PolyNovo transformed into a global medical technology company, achieving record sales growth and expanding its presence to 46 countries. The company remains committed to its business strategy and growth plans.
Polynovo Limited announced the appointment of Robert Douglas as a director, effective October 14, 2025. This appointment is part of the company’s strategic efforts to strengthen its leadership team and enhance its market position in the medical technology sector. The announcement does not indicate any current securities or contract interests held by the new director, suggesting a fresh start in his role.
PolyNovo Limited has announced the appointment of Mr. Robert Douglas as a new Non-Executive Director, with a resolution for his election to be proposed at the upcoming Annual General Meeting. Mr. Douglas brings extensive experience from his previous role as Global Chief Operating Officer at ResMed, and his expertise is expected to enhance the board’s skillset and governance, benefiting the company and its stakeholders.
PolyNovo Limited has appointed Bruce Peatey as the new CEO, effective December 1, 2025. With extensive experience in healthcare, medical devices, and biotechnology, Peatey brings valuable skills in managing quality and regulatory functions, strategic business development, and market expansion. His leadership is expected to drive PolyNovo’s growth into new markets and enhance its international presence, particularly in the outpatient sector. The company anticipates that Peatey’s expertise and established relationships in the industry will inform its strategic approach to distribution in the US and key international markets.
PolyNovo Limited has appointed Mr. Robert Douglas as a Non-Executive Director to its Board. Mr. Douglas brings over 35 years of experience in medical device technology and public company governance, with a strong background in digital health and international business expansion. His previous roles at ResMed and current position with Globus Medical highlight his expertise in patient data management and cloud technology, which are expected to benefit PolyNovo’s strategic growth and innovation efforts.
Polynovo Limited has announced a change in the director’s interest, with David Williams acquiring an additional 55,000 ordinary shares through Moggs Creek Pty Ltd, a related entity. This acquisition, valued at $87,997.91, increases his total holdings to 21,655,000 shares, reflecting confidence in the company’s market position and potential growth, which may positively impact stakeholders’ perception.
Polynovo Ltd has announced that Citigroup Global Markets Australia Pty Limited and its related entities have ceased to be substantial holders in the company as of September 16, 2025. This change in substantial holding reflects a decrease in Citigroup’s relevant interest in Polynovo’s voting securities, which may impact the company’s shareholder structure and market perception.
PolyNovo Limited has announced a change in the director’s interest, with Dr. Robyn Elliott acquiring 20,000 ordinary fully paid shares through an on-market trade. This acquisition increases Dr. Elliott’s total holdings to 94,789 shares, reflecting a vote of confidence in the company’s prospects and potentially impacting investor perception positively.
Polynovo Limited has announced a change in the director’s interest, with David Williams acquiring an additional 50,030 ordinary shares through an on-market trade, increasing his total holdings to 21,600,000 shares. This acquisition, valued at $75,045, reflects continued confidence in the company’s prospects and could potentially influence investor perception positively.
Polynovo Limited has announced a change in the director’s interest in securities, specifically regarding David Williams, a director and controller of Moggs Creek Pty Ltd. The change involved the acquisition of 61,335 ordinary shares by Moggs Creek Pty Ltd, a related entity of Mr. Williams, through an on-market trade, increasing his total holdings to 21,549,970 shares. This transaction, valued at $85,975.35, reflects an active engagement in the company’s stock by its director, potentially indicating confidence in the company’s future performance.
PolyNovo Limited announced promising results from a randomized controlled trial evaluating its NovoSorb BTM product for post-surgical diabetes-related foot wounds. The study demonstrated that NovoSorb BTM significantly accelerates healing of large wounds compared to standard care, reducing the time to complete healing by over four months. This positions NovoSorb BTM as a valuable option in the limited treatment landscape for diabetic foot wounds, potentially influencing outpatient adoption and treatment practices, especially in the U.S. if CMS pricing changes in 2026.
PolyNovo Limited has requested a trading halt on its securities pending the release of an announcement related to a clinical trial. The trial investigates the effectiveness of NovoSorb BTM combined with negative pressure wound therapy compared to standard care in treating neuroischemic diabetic wounds. This announcement could have significant implications for PolyNovo’s market positioning and stakeholder interests, as it pertains to the potential efficacy of their product in a critical area of wound care.
Polynovo Limited announced a change in the director’s interest notice, indicating that Director David Williams has acquired an additional 31,000 ordinary shares through Moggs Creek Pty Ltd, a related entity. This acquisition, completed via an on-market trade, reflects a continued investment in the company, potentially signaling confidence in Polynovo’s strategic direction and market position.
PolyNovo Limited announced a change in the director’s interest, with Mr. Leon Hoare acquiring an additional 20,000 ordinary fully paid shares through his personal super account. This transaction, executed via an on-market trade, reflects a continued commitment by the director to the company’s growth and stability, potentially signaling confidence in PolyNovo’s future prospects to stakeholders.
Polynovo Limited has announced a change in the director’s interest notice involving David Williams, a director and controller of Moggs Creek Pty Ltd. The company operates in the medical technology industry, focusing on the development and commercialization of innovative wound care solutions. The announcement details that Moggs Creek Pty Ltd, a related entity of Mr. Williams, acquired 37,000 ordinary shares at a total value of $51,980.04 through an on-market trade. This acquisition increases the total number of shares held by Mr. Williams to 21,457,635. The transaction did not occur during a closed period, indicating compliance with trading regulations.
PolyNovo’s 2025 Annual Report highlights its strategic focus on expanding global reach and product offerings, particularly with NovoSorb MTX. The company is enhancing its market position by scaling operations and driving growth through innovation, which is expected to benefit stakeholders by improving patient outcomes and increasing market penetration.